Drug company AbbVie ABBV-0.70%decrease; red down pointing triangle has agreed to buy biotech ImmunoGen for $10.1 billion in a new bet on one of the most promising novel drug technologies for ...

Nealy all acquirers must pay well over the market price to buy out other companies. AbbVie isn't investing in ImmunoGen, like Berkshire Hathaway when it buys Apple stock. AbbVie will own it ...

Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments. The drugmaker will pay $31.26 ...

(Reuters) — AbbVie said on Thursday it will buy ImmunoGen for $10.1 billion, underscoring a growing interest from large drugmakers in a promising class of targeted cancer therapies. Through the ...

ImmunoGen’s board unanimously agreed on the AbbVie merger, culminating in a joint announcement the following day. AbbVie’s buy was at a 94.6% premium to ImmunoGen’s closing share price on ...

Nov 30 (Reuters) - AbbVie (ABBV.N), opens new tab will buy ImmunoGen (IMGN.O), opens new tab for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to acquire a maker of ...

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

AbbVie announced on Thursday its intent to buy ImmunoGen for $10.1 billion, or $31.26 per share, nearly double ImmunoGen’s share price of $16.06 at market close the day before the deal.

Buying ImmunoGen and Cerevel Therapeutics should make AbbVie more competitive in oncology and neuroscience. Those deals don't make AbbVie an obvious buy, but other factors might. During 2023 ...

In October, Merck & Co. Inc. agreed to pay as much as $22 billion to buy the rights to sell three ADCs under development at Japan’s Daiichi Sankyo Co. AbbVie will gain ImmunoGen’s Elahere ...